Caris Life Sciences (CAI) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Evercore ISI Group | Maintained | Outperform | $26.00 from $25.00 | Aug 6, 2026 |
| BTIG | Maintained | Buy | $33.00 from $32.00 | Aug 6, 2026 |
| Evercore ISI Group | Maintained | Outperform | $25.00 from $30.00 | Jul 6, 2026 |
| BTIG | Maintained | Buy | $32.00 | Jul 2, 2026 |
| Wolfe Research | Initiated Coverage | Peer Perform | — | Jun 2, 2026 |
| BTIG | Maintained | Buy | $32.00 from $38.00 | May 8, 2026 |
| JP Morgan | Maintained | Overweight | $30.00 from $35.00 | May 8, 2026 |
| Citigroup | Maintained | Buy | $28.00 from $35.00 | May 8, 2026 |
| Jefferies | Initiated Coverage | Buy | $28.00 | Apr 13, 2026 |
| Piper Sandler | Initiated Coverage | Neutral | $21.00 | Apr 10, 2026 |
| Evercore ISI Group | Maintained | Outperform | $30.00 from $34.00 | Apr 6, 2026 |
| Canaccord Genuity | Maintained | Hold | $22.00 from $30.00 | Mar 13, 2026 |
| BTIG | Maintained | Buy | $38.00 from $45.00 | Feb 27, 2026 |
| Evercore ISI Group | Maintained | Outperform | $34.00 from $38.00 | Feb 27, 2026 |
| Baird | Maintained | Outperform | $28.00 from $26.00 | Feb 27, 2026 |
| Baird | Initiated Coverage | Outperform | $26.00 | Feb 17, 2026 |
| Canaccord Genuity | Maintained | Hold | $30.00 from $28.00 | Dec 22, 2025 |
| Canaccord Genuity | Initiated Coverage | Hold | $28.00 | Dec 2, 2025 |
| Citigroup | Maintained | Buy | $42.00 from $34.00 | Aug 13, 2025 |
| Evercore ISI Group | Maintained | Outperform | $40.00 from $33.00 | Aug 13, 2025 |
Frequently asked questions
Is CAI a buy, sell, or hold?
Analysts covering Caris Life Sciences currently average a Buy rating: 10 buy, 3 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CAI?
On Aug 6, 2026, Evercore ISI Group maintained Caris Life Sciences at Outperform with a price target of $26.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.